real-world data

Videos

Subcutaneous Rituximab Prefered Over Intravenous Formulation for NHL in Clinical Practice

01/14/2021

Journal of Clinical Pathways

Videos

Real-World Biomarker Testing, Treatment Patterns in CLL/SLL

12/17/2020

Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.

Anthony Mato, MD, discusses...

12/17/2020

Journal of Clinical Pathways

Conference Coverage

Real-World Toxicity and Tolerability of Ibrutinib for CLL or SLL

12/09/2020

Journal of Clinical Pathways

Conference Coverage

Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting

12/06/2020

Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.

Results from a real-world study...

12/06/2020

Journal of Clinical Pathways

Conference Coverage

Ibrutinib Dose Reductions and Discontinuations for CLL in Routine Practice vs Clinical Trials

12/04/2020

Journal of Clinical Pathways

Case Study

Patient-Reported Outcomes: Investing in Real-Time Intervention to Improve Care

04/16/2019

Diane Denny , DBA, MHA, FACHE, CPHQ, CPPS;

Brandon Bosch , MPH;

Scott R. Hartman , MS, PMP;

Morgan Hannaford , MA;

Abstract: A geographically dispersed network of hospitals began the journey to integrate patient-reported outcome (PRO) data in the form of quality-of-life measurement into daily operations beginning in 2012, moving...

...

04/16/2019

Journal of Clinical Pathways

Research in Review

Patient Outcomes Negatively Affected by Gaps in Cancer Care

07/19/2017

JCP Editors

Recent research suggests that 73% of patients with cancer do not discuss the cost of care with their care team, published by the Cancer Support Community (July 18, 2017). ----- Related Content Improving Patient...

Recent...

07/19/2017

Journal of Clinical Pathways

Research in Review

Targeted Therapy Improves Survival in Older Patients With B-Cell Malignancy

06/27/2017

JCP Editors

A targeting agent is more effective in improving progression-free survival (PFS) and overall survival (OS) than conventional therapy in older patients with a treatment-naïve B-cell malignancy, according to research...

A...

06/27/2017

Journal of Clinical Pathways

Research in Review

NSCLC Treatment Patterns, OS Data Aids Clinical Practice Benchmark Initiatives

06/26/2017

JCP Editors

Results of a recent study offer insight into the effects of shifting treatment patterns of non-small cell lung cancer (NSCLC) treatment on patient outcomes, and for furthering community oncology benchmark...

...

06/26/2017

Journal of Clinical Pathways

Department

Pazopanib More Cost-Effective Than Sunitinib for Patients With Renal Cell Carcinoma

04/12/2017

JCP Editors

Medicare patients with advanced renal cell carcinoma benefit from lower costs and hospital admissions if treated with pazopanib (Votrient, Novartis) rather than sunitinib (Sutent, Pfizer). Advanced renal cell...

...

04/12/2017

Journal of Clinical Pathways